VSTM 0,83$ o esa zona seria una entrada muy interesante con un risk reward bastante aceptable, al menos para mi claro, y nunca hay que descartar la posibilidad que los visite
el 10 de agosto vendieron una drug que tenian aprobada,
un chicharro con cash hasta 2024 es raro raro,
un chicharro con una drug aprobada anteirormente también xd
dejan de lado comercializaciones y cosas y se quedan con la investigación del resto de pipeline
algo de covid también hay por ahi,
es chicharro "premium" que dico, pero chicharro, a fin de cuentas...
------
Verastem Oncology Signs Definitive Agreement to Sell COPIKTRA® (duvelisib) Rights to Secura Bio to Focus on Development of VS-6766 and Defactinib in KRAS Mutant Solid Tumors
Verastem Will Receive $70 Million Up-Front with Total Deal Value up to $311 Million, Plus Double-Digit Sales Royalties
Upon Closing, Verastem’s Current Programs Will Be Funded Until At Least 2024 to Develop VS-6766 and Defactinib in Low-Grade Serous Ovarian Cancer and KRAS Mutant Non-Small Cell Lung Cancer
Phase 2 Registration-Directed Trials Expected to Commence by Year End 2020 in Both Low-Grade Serous Ovarian Cancer and KRAS Mutant Non-Small Cell Lung Cancer
Enrollment in Ongoing Investigator-Initiated Phase 1/2 FRAME Study of VS-6766 and Defactinib Now Expanding to Include Pancreatic, KRAS Mutant Endometrial and KRAS-G12V Non-Small Cell Lung Cancer Cohorts
Terms of the Definitive Sale Agreement
Verastem will receive an up-front payment of $70 million upon the closing of the transaction and is eligible to receive up to a total deal value of $311 million if certain regulatory and sales-based milestones are successfully met by Secura Bio and COPIKTRA’s other rest-of-world partners, including:
| · | A total of $45 million from two separate milestone payments for U.S. Food and Drug Administration (FDA) and European Medicines Agency approvals of COPIKTRA with label indicated for peripheral T-cell lymphoma
| · | A total of $50 million for cumulative worldwide net sales of COPIKTRA beginning at $100 million of cumulative net sales
| · | Verastem will receive low double-digit royalties on net sales over $100 million in U.S., Europe and the United Kingdom
| · | Verastem will also receive 50% of licensing milestones (up to $146 million) and royalties outside of U.S., Europe and the United Kingdom